GSK's Global HIV Business ViiV Healthcare Completes Transactions to Acquire Bristol-Myers Squibb's R&D HIV Assets

London (ots/PRNewswire) -

GlaxoSmithKline plc (LSE: GSK) today announced that ViiV
Healthcare, the global specialist HIV company majority owned by GSK,
with Pfizer Inc. and Shionogi Limited as shareholders, has completed
two previously announced transactions with Bristol-Myers Squibb to
acquire its late-stage HIV R&D assets and its portfolio of
preclinical and discovery stage HIV research assets. The completion
of both transactions follows antitrust approval by the relevant
regulatory authorities in the US, with the integration process
beginning immediately.

Dominique Limet, CEO, ViiV Healthcare, said: "As a result of these
transactions, ViiV Healthcare now has one of the most robust HIV
pipelines in the industry. The assets that we have acquired
complement our existing portfolio and could lead to new medicines and
combinations addressing a broad range of treatment and prevention
needs of people living with HIV."

Under the terms of the transactions, ViiV Healthcare acquired
late-stage HIV R&D assets from Bristol-Myers Squibb for an initial
upfront payment of $317 million followed by development and first
commercial sale milestones of up to $518M, and tiered royalties on
sales. ViiV Healthcare also acquired Bristol-Myers Squibb's
preclinical and discovery stage HIV research business for an upfront
payment of $33 million, followed by development and first commercial
sales milestones of up to $587M, and further consideration contingent
on future sales performance.

ViiV Healthcare has acquired:

- Late stage assets, including fostemsavir (BMS-663068), an
attachment inhibitor currently in phase III development for heavily
treatment experienced patients. Fostemsavir has received a
Breakthrough Therapy Designation from the FDA and is expected to be
filed for regulatory approval in 2018. The second late stage asset
is a maturation inhibitor (BMS-955176), and is currently in phase
IIb development for both treatment-naive and treatment experienced
patients. A back-up maturation inhibitor candidate (BMS-986173) is
also included in the purchase.
- Assets in preclinical and discovery phases of development including
a novel biologic (BMS-986197) with a triple mechanism of action, an
additional maturation inhibitor, an allosteric integrase inhibitor
and a capsid inhibitor.

GSK - one of the world's leading research-based pharmaceutical and
healthcare companies - is committed to improving the quality of human
life by enabling people to do more, feel better and live longer. For
further information please visit http://www.gsk.com.

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in
November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE)
dedicated to delivering advances in treatment and care for people
living with HIV. Shionogi joined in October 2012. The company's aim
is to take a deeper and broader interest in HIV/AIDS than any company
has done before and take a new approach to deliver effective and new
HIV medicines, as well as support communities affected by HIV. For
more information on the company, its management, portfolio, pipeline,
and commitment, please visit http://www.viivhealthcare.com

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual results
to differ materially from those projected. Such factors include, but
are not limited to, those described under Item 3.D 'Risk factors' in
the company's Annual Report on Form 20-F for 2014.

Registered in England & Wales: No. 3888792

Registered Office: 980 Great West Road Brentford, Middlesex TW8
9GS

ots Originaltext: GlaxoSmithKline Plc
Im Internet recherchierbar: http://www.presseportal.de

Contact:
UK Media enquiries: David Mawdsley +44 (0) 20 8047 5502 (London) Simon
Steel +44 (0) 20 8047 5502 (London) David Daley +44 (0) 20 8047 5502
(London) US Media enquiries: Kathleen Cuca
+1 215 859 1922 (Philadelphia) Sarah Spencer +1 215 751 3335
(Philadelphia) Mary Anne Rhyne +1 919 483 0492 (North Carolina)
Analyst/Investor enquiries: Ziba Shamsi +44 (0) 20 8047 5543 (London)
Tom Curry + 1 215 751 5419 (Philadelphia) Gary Davies +44 (0) 20 8047
5503 (London) James Dodwell +44 (0) 20 8047 2406 (London) Jeff
McLaughlin +1 215 751 7002 (Philadelphia)